1. Volume 73, Issue 3, Pages 427-435 (March 2018)
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial 
Christopher C. Parker, Robert E. Coleman, Oliver Sartor, Nicholas J. Vogelzang, David Bottomley, Daniel Heinrich, Svein I. Helle, Joe M. O'Sullivan, Sophie D. Fosså, Aleš Chodacki, Paweł Wiechno, John Logue, Mihalj Seke, Anders Widmark, Dag Clement Johannessen, Peter Hoskin, Nicholas D. James, Arne Solberg, Isabel Syndikus, Jan Kliment, Steffen Wedel, Sibylle Boehmer, Marcos Dall’Oglio, Lars Franzén, Øyvind S. Bruland, Oana Petrenciuc, Karin Staudacher, Rui Li, Sten Nilsson 
European Urology 
Volume 73, Issue 3, Pages (March 2018)
DOI: /j.eururo
Copyright © 2017 European Association of Urology Terms and Conditions

2. Fig. 1
ALSYMPCA study timeline. ALSYMPCA=Alpharadin in Symptomatic Prostate Cancer; W=week; Y=year.
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions

3. Fig. 2
CONSORT diagram. a One patient in the placebo group received one injection of radium-223 (week 0) and is included in the radium-223 safety analysis. b Two (<1%) radium-223 and two (<1%) placebo patients’ study completion pages were not received.
European Urology  , DOI: ( /j.eururo )
Copyright © 2017 European Association of Urology Terms and Conditions